Free Trial

OmniAb Q3 2023 Earnings Report

OmniAb logo
$3.73 -0.03 (-0.80%)
(As of 12:44 PM ET)

OmniAb EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.14
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

OmniAb Revenue Results

Actual Revenue
$5.48 million
Expected Revenue
$11.37 million
Beat/Miss
Missed by -$5.89 million
YoY Revenue Growth
N/A

OmniAb Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

This drone stock is setting up to transform medical supply delivery (Ad)

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth

OmniAb Earnings Headlines

AI Crypto Tool Could Send One Coin SOARING…
The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto project
Stifel Nicolaus Keeps Their Buy Rating on OmniAb (OABI)
See More OmniAb Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OmniAb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OmniAb and other key companies, straight to your email.

About OmniAb

OmniAb (NASDAQ:OABI), a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

View OmniAb Profile

More Earnings Resources from MarketBeat

Upcoming Earnings